PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Study: Autophagy predicts which cancer cells live and die when faced with anti-cancer drugs

2014-01-11
(Press-News.org) Contact information: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Study: Autophagy predicts which cancer cells live and die when faced with anti-cancer drugs When a tumor is treated with an anti-cancer drug, some cells die and, unfortunately, some cells tend to live. A University of Colorado Cancer Center study published in the journal Nature Cell Biology details a possible difference between the susceptible and resistant cells: the rate at which cells are able to cleanse themselves via the process known as autophagy.

"In these studies, say we treat cells with the IC-50 of a drug - at that dose, 50 percent of cells should live and 50 percent of cells should die. But the fundamental question is why does cell A die whereas cell B lives? What we show is that the difference may be due to random variation in the amount of autophagy that's going on," says Andrew Thorburn, PhD, deputy director of the CU Cancer Center.

Previous studies show that autophagy promotes cell survival – under conditions of stress or shortage, cells break down non-necessary components to provide energy or use the same strategy to prevent cellular damage by degrading and recycling potentially damaging proteins. And so it seems logical that cancer cells with low autophagy would have high mortality when faced with anti-cancer drugs. However, the current study shows that rates of cell death may increase or decrease depending on levels of autophagy and the specific mechanism of the anti-cancer drug.

"We separated cancer cells into populations with low and high autophagy and then treated them with two drugs, both of which should activate death. Interestingly, when treated with the first drug, cells with high autophagy had the highest mortality. But then when treated with the second drug, cells with low autophagy had the highest mortality. Depending on the drug, the effect of autophagy was opposite," Thorburn says.

Specifically, Thorburn and colleagues including first author Jacob Gump, PhD, treated high- and low-autophagy cell populations with chemicals TRAIL and Fas ligand, which activate cells' death receptors. Cells treated with these chemicals are "told" to die and as the researchers expected, some cells in all populations underwent the programmed cell death known as apoptosis. However, cells with high autophagy were more sensitive to treatment with Fas ligand, whereas cells with low autophagy were more sensitive to TRAIL. Similar differences were seen across types of cancer cells - in some cancers, autophagy protects against these drugs and in others autophagy makes cells more susceptible.

While the work does not necessarily add to our understanding of how autophagy aids cell survival, the group showed how it creates cell death in some tumors when confronted with some drugs: a protein known as FAP-1 is present in some but not all cancer cells where it serves to decrease the ability of Fas ligand to kill the cells. Autophagy degrades this cell-survival protein and this, in turn, makes cells more susceptible to Fas ligand but only in the cells where FAP-1 is normally present.

"If similar variation occurs in other contexts, a cancer cell you're trying to kill could be more or less resistant to whatever you're using to try to kill it depending on its level of autophagy," Thorburn says. Additionally, Thorburn points out that cells in these lab studies tend to be homogenous in their levels of autophagy compared to cells in natural tumor environments. It is likely, he says, these laboratory results will be magnified in actual tumors, where levels of autophagy tend to vary more widely.

While Fas ligand and TRAIL agonists are used in the lab only at this time, Thorburn says the next step in this line of research is to perform similar experiments with drugs that could be used in people.

### END


ELSE PRESS RELEASES FROM THIS DATE:

Text messaging boosts flu vaccine rates in pregnant women

2014-01-11
Text messaging boosts flu vaccine rates in pregnant women January 10, 2014 --A study by researchers at the Mailman School of Public Health evaluated the impact of text messaging reminders for influenza vaccine in a low-income obstetric ...

Complementary medicine in wide use to treat children with autism, developmental delay

2014-01-11
Complementary medicine in wide use to treat children with autism, developmental delay

Study shows large carnivore numbers and range declining worldwide

2014-01-10
Study shows large carnivore numbers and range declining worldwide MISSOULA – New research co-written by University of Montana scientists finds steep declines in the worldwide populations and habitat range of 31 large carnivore species. The analysis, ...

Harvard scientists control cells following transplantation, from the inside out

2014-01-10
Harvard scientists control cells following transplantation, from the inside out New work by Jeffrey Karp, Ph.D., has potential to make cell therapies more functional and efficient Harvard stem cells scientists at Brigham and Women's Hospital and MIT can now engineer ...

Indigenous groups more vulnerable in the fight against flu

2014-01-10
Indigenous groups more vulnerable in the fight against flu Research indicated that some Indigenous people such as in Alaska and Australia displayed limited immunity response to the effects of influenza. Published in the Journal Proceedings of the National ...

Living on islands makes animals tamer

2014-01-10
Living on islands makes animals tamer Study confirms Darwin's observations and numerous anecdotal reports of island tameness, says UC Riverside's Theodore Garland RIVERSIDE, Calif. — Most of us have seen pictures and probably YouTube videos of "tame" animals ...

Evidence of harmful effect of bisphenol A-based plastics

2014-01-10
Evidence of harmful effect of bisphenol A-based plastics Function and regeneration of switch proteins impaired Bisphenol A impairs the function of proteins that are vital for growth processes in cells. This finding has been reported by researchers from the ...

Regorafenib: hint of minor added benefit

2014-01-10
Regorafenib: hint of minor added benefit Advantage in overall survival, but disadvantage in severe side effects Regorafenib (trade name: Stivarga) has been approved in Germany since August 2013 for adults with metastatic colorectal ...

KIT researchers develop artificial bone marrow

2014-01-10
KIT researchers develop artificial bone marrow This news release is available in German. Artificial bone marrow may be used to reproduce hematopoietic stem cells. A prototype has now been developed by scientists of KIT, the Max Planck Institute for Intelligent ...

Study quantifies costs when failed banks shun financial transparency

2014-01-10
Study quantifies costs when failed banks shun financial transparency New study shows that more transparent accounting helps bidders, lowers costs when financial institutions fail Good accounting isn't just a hallmark of a well-run company: As a new study ...

LAST 30 PRESS RELEASES:

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate

Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative

Structure dictates effectiveness, safety in nanomedicine

Mission accomplished for the “T2T” Hong Kong Bauhinia Genome Project

[Press-News.org] Study: Autophagy predicts which cancer cells live and die when faced with anti-cancer drugs